Platinum Equity completes acquisition of Owens & Minor P&HS: What changes now and what’s at stake for the standalone healthcare distributor?

Platinum Equity has officially completed its acquisition of the Owens & Minor Products & Healthcare Services business, now rebranded as Owens & Minor P&HS. The deal positions the newly private, vertically integrated medical supply distributor for a strategic overhaul under Platinum’s carve-out model, while the original parent company retains a 5 percent stake and pivots its future under a new name, Accendra Health Inc.

The transaction, which closed on December 31, 2025, marks a decisive split in the future direction of Owens & Minor’s assets, handing operational control of its core distribution business to one of the most active private equity players in the healthcare supply chain space. Platinum Equity’s immediate goal is to scale the standalone entity through operational restructuring, proprietary product expansion, and sharper supply chain performance, all while preserving the legacy Owens & Minor brand.

Why Platinum Equity’s carve-out strategy could reshape the healthcare supply chain model in 2026

Platinum Equity’s acquisition of Owens & Minor P&HS fits squarely within its long-standing strategy of extracting overlooked value from corporate carve-outs. The firm brings three decades of executional experience in acquiring non-core divisions from global corporations—including Caterpillar, Kohler, and Emerson Electric—and then transforming them into agile, focused operators.

In Owens & Minor P&HS, Platinum inherits a business with deep-rooted customer relationships, broad acute care market reach, and entrenched distribution infrastructure. But the business also arrives with the baggage of prior underperformance under a corporate structure that often struggled to balance manufacturing and logistics complexity with capital market expectations.

What Platinum gains is the freedom to reset priorities—decoupling legacy overhead, accelerating investments in proprietary SKUs, and implementing granular operational metrics across the supply chain and fulfillment layers. According to Platinum Equity Co-President Jacob Kotzubei, the firm will prioritize agility and resilience, positioning P&HS to respond more effectively to demand volatility and industry-specific shocks like pandemic-driven procurement bottlenecks or payer reimbursement realignments.

This focus on vertical integration—from manufacturing to last-mile delivery—is especially crucial in a post-COVID world where hospital systems and integrated delivery networks increasingly demand not just scale but reliability, compliance visibility, and SKU-level traceability.

How will Owens & Minor P&HS compete with larger med-surg distributors after separation?

As a standalone business, Owens & Minor P&HS is now tasked with defending and expanding its footprint against much larger med-surg distribution peers such as Cardinal Health, Medline Industries, and McKesson Corporation. The key to unlocking differentiation will likely lie in three areas: fulfillment performance, proprietary product development, and customer intimacy.

Platinum Managing Director Matthew Louie emphasized continuity and incremental transformation as cornerstones of the firm’s approach. The strategic roadmap will likely include investing in supply chain digitization, tightening inventory and demand forecasting algorithms, and selectively reshoring or nearshoring key product lines to reduce exposure to geopolitical risk.

Owens & Minor P&HS’s ability to scale its private-label portfolio—especially in high-margin categories like surgical drapes, PPE, and sterile kits—will also determine how successfully it can move beyond commoditized distribution margins. This aligns with Platinum’s historic playbook of targeting product line expansions that increase control over margin leakage and customer lock-in.

However, execution risks remain high. A carve-out of this magnitude often involves complex system separation, transitional service agreements with the parent, and potential customer or supplier renegotiations. The ability of Platinum to retain operational leadership talent and institutional healthcare clients during the transition period will be a critical determinant of early success.

What the Accendra Health rebrand signals about the future of Owens & Minor’s remaining assets

While Platinum takes operational ownership of P&HS, the original parent company is not exiting the sector altogether. Owens & Minor Inc. will retain a 5 percent equity interest in the carved-out business and simultaneously rebrand its remaining segments as Accendra Health Inc., effective the same day as the transaction closing.

The name change underscores a strategic reorientation away from broad medical distribution toward higher-margin service verticals, possibly centered around its Patient Direct business or technology-enabled healthcare services. This rebrand may also reflect an effort to reset investor perception, streamline capital allocation, and attract growth-oriented institutional interest as a redefined healthcare platform company.

Whether Accendra Health Inc. can unlock sustained valuation uplift as a streamlined services-first healthcare company will depend in part on how effectively it distances itself from the capital-intensive distribution legacy now transferred to Platinum Equity.

Investor sentiment and market context around private equity carve-outs in healthcare

Platinum Equity’s latest acquisition comes amid a renewed surge of private equity interest in healthcare logistics, particularly in businesses that straddle both product manufacturing and distribution. Macroeconomic tailwinds—such as an aging U.S. population, increased elective procedure volumes post-COVID, and ongoing hospital margin compression—are prompting providers to rethink supply partnerships.

Investors have generally viewed private equity-led carve-outs as a double-edged sword. On one hand, they bring much-needed operational focus and capital discipline. On the other, they often lead to aggressive cost-cutting or leverage-driven strategies that may compromise long-term resilience unless managed carefully.

Platinum’s recent track record of healthcare-related carve-outs, such as its acquisition of LifeScan and Husky Technologies, shows a strong bias toward platform building rather than pure financial engineering. However, market observers will watch closely for early signs of product line rationalization or customer churn as the newly standalone entity navigates its transition year.

What regulatory or competitive risks could impact the success of this carve-out?

Given its position in the U.S. healthcare logistics backbone, Owens & Minor P&HS will remain subject to regulatory scrutiny around pricing transparency, contract fulfillment, and supply chain resilience. While not directly exposed to reimbursement risk like a payor or provider, the distributor operates in a highly compliance-sensitive environment, particularly for products deemed critical under public health emergency frameworks.

Competitively, the rising prevalence of GPO (Group Purchasing Organization)-led procurement, consolidated IDN contracts, and Amazon-like entrants into healthcare logistics will challenge Owens & Minor P&HS to define a clear differentiation thesis. The pressure to demonstrate operational excellence across its Richmond-based distribution core and national network will be intense.

Private equity ownership also brings a limited time horizon. Unless the business can demonstrate topline growth alongside margin improvement within a 3- to 5-year window, exit pathways such as a future IPO, SPAC transaction, or sale to a strategic acquirer may be less compelling. Execution risk is compounded by industry labor shortages and digital transformation lag.

Key takeaways on what Platinum Equity’s carve-out of Owens & Minor P&HS means for the healthcare industry

• Platinum Equity has completed the acquisition of Owens & Minor P&HS, creating a new standalone medical supply distribution business under private ownership.
• The original parent company retains a 5 percent equity interest and has rebranded its remaining operations as Accendra Health Inc., signaling a strategic pivot.
• The deal reflects Platinum’s carve-out strategy and focus on healthcare supply chain opportunities, leveraging its operational overhaul playbook.
• Owens & Minor P&HS will retain its legacy brand and target growth in proprietary products, fulfillment agility, and digital supply chain capabilities.
• Execution risks include transitional system decoupling, talent retention, customer churn, and integration of proprietary product strategies.
• The standalone distributor faces rising pressure from GPOs, hospital consolidation, and Amazon-style disruptors in medical logistics.
• Platinum Equity’s 3- to 5-year investment horizon may prompt aggressive operational moves to drive margin expansion and potential exit pathways.
• This transaction underscores the growing trend of private equity reshaping healthcare infrastructure businesses through targeted carve-outs.